Enrolling by invitationPhase 2NCT02402660
Phase 2 Tolerability and Effects of ALK-001 on Stargardt Disease
Studying Stargardt disease
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Alkeus Pharmaceuticals, Inc.
- Intervention
- ALK-001(drug)
- Enrollment
- 160 enrolled
- Eligibility
- 8-70 years · All sexes
- Timeline
- 2015 – 2026
Study locations (14)
- Alkeus Site, Phoenix, Arizona, United States
- Alkeus Site, Los Angeles, California, United States
- Alkeus Site, Aurora, Colorado, United States
- Alkeus Site, Gainesville, Florida, United States
- Alkeus Site, Miami, Florida, United States
- Alkeus Site, Indianapolis, Indiana, United States
- Alkeus Site, Baltimore, Maryland, United States
- Alkeus Site, Grand Rapids, Michigan, United States
- Alkeus Site, New York, New York, United States
- Alkeus Site, Westbury, New York, United States
- Alkeus Site, Houston, Texas, United States
- Alkeus Site, Salt Lake City, Utah, United States
- Alkeus Site, Silverdale, Washington, United States
- Alkeus Site, Milwaukee, Wisconsin, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT02402660 on ClinicalTrials.govOther trials for Stargardt disease
Additional recruiting or active studies for the same condition.
- RECRUITINGNCT07425574A Study to Learn How Stargardt-type Eye Conditions Progress in Children and AdultsAstellas Pharma Global Development, Inc.
- RECRUITINGPHASE1, PHASE2NCT07439887Phase 1/2 Open-Label Dose-Escalation Study to Evaluate Safety of a Single Intravitreal Injection of RTx-021 in Patients With Stargardt DiseaseRay Therapeutics, Inc.
- RECRUITINGPHASE1NCT07417566A Study of DC6001 Tablet in Healthy Chinese Adult SubjectsHeronova Pharmaceuticals
- RECRUITINGPHASE1, PHASE2NCT07161544A Study of AAVB-039 in Participants With Stargardt Disease (STGD1)AAVantgarde Bio Srl
- RECRUITINGPHASE1, PHASE2NCT06942572A Phase 1/2, First-in-Human Dose Escalation/Expansion Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of a Subretinal Injection of SB-007 in Subjects With Stargardt Disease (STGD1)Splice Bio
- RECRUITINGNCT06445322Prescreening Study to Identify Potential Stargardt Participants for ACDN-01 Clinical Trials (STARPATH)Ascidian Therapeutics, Inc
- RECRUITINGPHASE1, PHASE2NCT06467344Study to Evaluate ACDN-01 in ABCA4-related Stargardt Retinopathy (STELLAR)Ascidian Therapeutics, Inc
- RECRUITINGNCT06591806An Observational Study in Children and Adults With Stargardt DiseaseAAVantgarde Bio Srl